{"nctId":"NCT00511797","briefTitle":"SH T00186 Phase II/ III Optimal Drospirenone (DRSP) Dose Finding and Placebo-controlled Comparative Study","startDateStruct":{"date":"2007-07"},"conditions":["Dysmenorrhea"],"count":249,"armGroups":[{"label":"DRSP 1 mg/EE 20 μg","type":"EXPERIMENTAL","interventionNames":["Drug: SH T04740B"]},{"label":"DRSP 2 mg/EE 20 μg","type":"EXPERIMENTAL","interventionNames":["Drug: SH T04740F"]},{"label":"DRSP 3 mg/EE 20 μg","type":"EXPERIMENTAL","interventionNames":["Drug: SH T00186DF"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"SH T04740B","otherNames":[]},{"name":"SH T00186DF","otherNames":[]},{"name":"SH T04740F","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged 20 years or older at obtaining informed consent\n* Patients having the normal menstrual cycle (28+/-3 days) in the latest two menses before the final enrollment\n* Patients having a total dysmenorrhea score of at least 3 points in two menstrual cycles before the final enrollment\n\nExclusion Criteria:\n\n* Patients with ovarian chocolate cysts and symptomatic uterine fibroids (as defined in greater detail in the study protocol)\n* Patients with estrogen-dependent tumors (e.g. breast cancer, cancer of the uterine body or breast fibrocystic, etc.), and patients with cervical cancer or suspected cervical cancer (e.g. class III or greater in the cervical smear or endometrial smear examination.)\n* Patients with undiagnosed abnormal vaginal bleeding\n* Patients with thrombophlebitis, pulmonary embolism, cerebrovascular disease(including transient ischemic attack, etc.), or coronary artery disease(e.g. myocardial infarction and angina pectoris, etc.), or a history of those diseases\n* Patients aged 35 years or older who smoke at least 15 cigarettes per day\n* Patients with migraine accompanied by prodrome (e.g. scintillating scotoma or star-shaped scintillation)\n* Patients with pulmonary hypertension or valvular heart disease complicated by atrial fibrillation, and patients with a history of subacute bacterial endocarditis\n* Patients who are regularly taking nutritional products that contain St. John's Wort\n* Patients who underwent surgical treatment for endometriosis by laparotomy, or laparoscopy within 2 months prior to screening\n* Patients who need to use analgesics regularly for therapeutic objectives other than relief from the pain of dysmenorrhea during this study (occasional use permitted)","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Total Dysmenorrheal Score at Final Evaluation","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.52"},{"groupId":"OG001","value":"-2.1","spread":"1.51"},{"groupId":"OG002","value":"-1.9","spread":"1.63"},{"groupId":"OG003","value":"-1.0","spread":"1.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Dysmenorrheal Score at Cycle 1 up to Cycle 4","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":"1.40"},{"groupId":"OG001","value":"-2.1","spread":"1.49"},{"groupId":"OG002","value":"-1.8","spread":"1.67"},{"groupId":"OG003","value":"-0.8","spread":"1.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.40"},{"groupId":"OG001","value":"-2.3","spread":"1.57"},{"groupId":"OG002","value":"-1.9","spread":"1.50"},{"groupId":"OG003","value":"-1.1","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.34"},{"groupId":"OG001","value":"-2.3","spread":"1.52"},{"groupId":"OG002","value":"-2.1","spread":"1.34"},{"groupId":"OG003","value":"-1.0","spread":"1.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.55"},{"groupId":"OG001","value":"-2.3","spread":"1.41"},{"groupId":"OG002","value":"-2.1","spread":"1.54"},{"groupId":"OG003","value":"-1.0","spread":"1.63"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severity of Lower Abdominal Pain During Menstruation at Cycle 4","description":"Severity of lower abdominal pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"17","spread":null},{"groupId":"OG002","value":"11","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"19","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"14","spread":null},{"groupId":"OG003","value":"21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"11","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severity of Low Back Pain During Menstruation at Cycle 4","description":"Severity of low back pain during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"36","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null},{"groupId":"OG002","value":"18","spread":null},{"groupId":"OG003","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severity of Headache During Menstruation at Cycle 4","description":"Severity of headache during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"35","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"5","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Severity of Nausea or Vomiting During Menstruation at Cycle 4","description":"Severity of nausea or vomiting during menstruation was rated as none (none), mild (can be easily tolerated), moderate (noticeable, but does not interfere with daily activities), or severe (interferes with daily activities).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4","description":"Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea and use of analgesics. Higher score means it is more severe. 0=None, 6=Severest.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null},{"groupId":"OG003","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Visual Analogue Scale (VAS) for Dysmenorrhea at Times Other Than During Menstruation at Cycle 4","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-43.0","spread":"23.44"},{"groupId":"OG001","value":"-39.5","spread":"22.12"},{"groupId":"OG002","value":"-31.8","spread":"23.55"},{"groupId":"OG003","value":"-10.3","spread":"24.53"}]}]}]},{"type":"SECONDARY","title":"Visual Analogue Scale (VAS) for Pelvic Pain at Times Other Than During Menstruation at Cycle 4","description":"VAS is an unmarked scale on a line 100 mm in length, indicating from 0 mm (no pain) to 100 mm (worst pain a participant has ever experienced).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":"11.52"},{"groupId":"OG001","value":"5.4","spread":"11.78"},{"groupId":"OG002","value":"4.0","spread":"14.26"},{"groupId":"OG003","value":"11.5","spread":"20.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Endometrial Thickness After 4-cycle Treatment","description":"Endometrial thickness was measured via transvaginal ultrasound examination. The endometrium is the inner membrane of the uterus. During the menstrual cycle, the endometrium grows to a thick, blood vessel-rich, glandular tissue layer.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"4.11"},{"groupId":"OG001","value":"-7.1","spread":"3.25"},{"groupId":"OG002","value":"-6.3","spread":"4.07"},{"groupId":"OG003","value":"-0.1","spread":"2.79"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Episodes","description":"Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. An episode means a series of bleeding and/or spotting. The bleeding /spotting analyses are by intensity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"0.9"},{"groupId":"OG001","value":"3.3","spread":"1.3"},{"groupId":"OG002","value":"3.4","spread":"0.9"},{"groupId":"OG003","value":"2.9","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.9"},{"groupId":"OG001","value":"0.4","spread":"0.8"},{"groupId":"OG002","value":"0.3","spread":"0.5"},{"groupId":"OG003","value":"0.4","spread":"0.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.6"},{"groupId":"OG001","value":"0.4","spread":"1.1"},{"groupId":"OG002","value":"0.4","spread":"0.8"},{"groupId":"OG003","value":"0.2","spread":"0.6"}]}]}]},{"type":"SECONDARY","title":"Number of Bleeding / Spotting Days","description":"Bleeding data were captured from the diary a participant recorded by herself. Bleeding is a genital bleeding. Spotting is a slight genital bleeding with participant's experience. The bleeding /spotting analyses are by intensity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"8.7"},{"groupId":"OG001","value":"31.2","spread":"11.4"},{"groupId":"OG002","value":"29.2","spread":"11.0"},{"groupId":"OG003","value":"22.6","spread":"5.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21.3","spread":"5.9"},{"groupId":"OG001","value":"19.3","spread":"8.8"},{"groupId":"OG002","value":"18.6","spread":"6.5"},{"groupId":"OG003","value":"17.4","spread":"4.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":"7.0"},{"groupId":"OG001","value":"11.9","spread":"7.6"},{"groupId":"OG002","value":"10.5","spread":"8.2"},{"groupId":"OG003","value":"5.2","spread":"2.5"}]}]}]},{"type":"SECONDARY","title":"Participants With Withdrawal Bleeding","description":"Withdrawal bleedings were defined as bleedings while a participant takes placebo tablets.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"50","spread":null},{"groupId":"OG002","value":"49","spread":null},{"groupId":"OG003","value":"47","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Intracyclic Bleeding","description":"Intracyclic bleedings were defined as bleedings while a participant takes active drugs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Non-heavy Intracyclic Bleeding","description":"Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"7","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With Non-heavy Withdrawal Bleeding","description":"Non-heavy bleedings were defined as those other than heavy bleeding (less or normal bleeding).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"44","spread":null},{"groupId":"OG002","value":"42","spread":null},{"groupId":"OG003","value":"38","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Carbohydrate Antigen-125 (CA125) After 4-cycle Treatment","description":"CA125 is a laboratory parameter giving an indication of having tumor, whose elevated levels that were defined by a lab suggest a potential tumor.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.78","spread":null},{"groupId":"OG001","value":"0.53","spread":null},{"groupId":"OG002","value":"-3.79","spread":null},{"groupId":"OG003","value":"0.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum C-reactive Protein (CRP) After 4-cycle Treatment","description":"CRP is a laboratory parameter giving an indication of inflammation, whose elevated levels that were defined by a lab suggest a potential inflammation.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.015","spread":null},{"groupId":"OG001","value":"0.042","spread":null},{"groupId":"OG002","value":"-0.014","spread":null},{"groupId":"OG003","value":"-0.175","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Estradiol Level After 4-cycle Treatment","description":"Estradiol is a predominant sex hormone that presents in female.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.32","spread":null},{"groupId":"OG001","value":"-42.23","spread":null},{"groupId":"OG002","value":"-98.02","spread":null},{"groupId":"OG003","value":"49.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Serum Progesterone Level at Cycle 4","description":"Progesterone is a steroid hormone involving in the female menstrual cycle, pregnancy, etc.","paramType":"MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.93","spread":null},{"groupId":"OG001","value":"-8.23","spread":null},{"groupId":"OG002","value":"-9.37","spread":null},{"groupId":"OG003","value":"-0.27","spread":null}]}]}]},{"type":"POST_HOC","title":"Change From Baseline for Total Pelvic Pain Score at Times Other Than During Menstruation at Cycle 4","description":"Total pelvic pain score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":"1.19"},{"groupId":"OG001","value":"-0.3","spread":"1.12"},{"groupId":"OG002","value":"-0.1","spread":"1.06"},{"groupId":"OG003","value":"0.1","spread":"1.22"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (1)","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.46"},{"groupId":"OG001","value":"-2.4","spread":"1.50"},{"groupId":"OG002","value":"-1.9","spread":"1.49"},{"groupId":"OG003","value":"-1.2","spread":"1.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"1.54"},{"groupId":"OG001","value":"-1.9","spread":"1.49"},{"groupId":"OG002","value":"-1.9","spread":"1.75"},{"groupId":"OG003","value":"-0.8","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.0","spread":"1.30"},{"groupId":"OG001","value":"-2.4","spread":"0.99"},{"groupId":"OG002","value":"-1.5","spread":"1.39"},{"groupId":"OG003","value":"-0.7","spread":"1.65"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.57"},{"groupId":"OG001","value":"-2.0","spread":"1.64"},{"groupId":"OG002","value":"-2.2","spread":"1.74"},{"groupId":"OG003","value":"-1.1","spread":"1.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.63"},{"groupId":"OG001","value":"-2.1","spread":"1.52"},{"groupId":"OG002","value":"-1.8","spread":"1.73"},{"groupId":"OG003","value":"-1.0","spread":"1.47"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"1.00"},{"groupId":"OG001","value":"-2.1","spread":"1.49"},{"groupId":"OG002","value":"-2.3","spread":"1.37"},{"groupId":"OG003","value":"-1.0","spread":"1.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.62"},{"groupId":"OG001","value":"-2.0","spread":"1.50"},{"groupId":"OG002","value":"-2.1","spread":"1.61"},{"groupId":"OG003","value":"-1.1","spread":"1.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"1.42"},{"groupId":"OG001","value":"-2.3","spread":"1.53"},{"groupId":"OG002","value":"-1.8","spread":"1.66"},{"groupId":"OG003","value":"-0.8","spread":"1.27"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Subgroups (2)","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"1.53"},{"groupId":"OG001","value":"-2.1","spread":"1.51"},{"groupId":"OG002","value":"-1.9","spread":"1.63"},{"groupId":"OG003","value":"-1.0","spread":"1.53"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"1.62"},{"groupId":"OG001","value":"-1.9","spread":"1.32"},{"groupId":"OG002","value":"-2.2","spread":"1.72"},{"groupId":"OG003","value":"-1.0","spread":"2.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.47"},{"groupId":"OG001","value":"-2.2","spread":"1.62"},{"groupId":"OG002","value":"-1.8","spread":"1.61"},{"groupId":"OG003","value":"-1.0","spread":"1.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"1.59"},{"groupId":"OG001","value":"-2.1","spread":"1.28"},{"groupId":"OG002","value":"-2.3","spread":"1.96"},{"groupId":"OG003","value":"-1.1","spread":"2.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"1.49"},{"groupId":"OG001","value":"-2.1","spread":"1.62"},{"groupId":"OG002","value":"-1.9","spread":"1.55"},{"groupId":"OG003","value":"-1.0","spread":"1.35"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.28"},{"groupId":"OG001","value":"-1.9","spread":"1.36"},{"groupId":"OG002","value":"-1.8","spread":"1.44"},{"groupId":"OG003","value":"-1.0","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"1.75"},{"groupId":"OG001","value":"-2.6","spread":"1.77"},{"groupId":"OG002","value":"-2.4","spread":"2.06"},{"groupId":"OG003","value":"-1.1","spread":"1.65"}]}]}]},{"type":"POST_HOC","title":"Change From Baseline in Total Dysmenorrheal Score at Final Evaluation in Patients Without Previous Medication","description":"Total dysmenorrheal score was defined as sum of 2 sub-scores: severity of dysmenorrhea (none: 0, mild: 1, moderate: 2, severe: 3) and use of analgesics (none: 0, mild: 1, moderate: 2, severe: 3). Total possible best is 0, and total possible worst is 6. Note: used with permission of Nobelpharma Co., Ltd. from the phase 3 clinical study protocol (Prog Med 2005:25 (3):739-758) of IKH-01 in dysmenorrhea (associated with endometriosis) (Nobelpharma Co., Ltd.)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":62},"commonTop":["Headache","Nasopharyngitis","Dysmenorrhoea","Nausea","Genital haemorrhage"]}}}